<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03125824</url>
  </required_header>
  <id_info>
    <org_study_id>Soliton 2017-001</org_study_id>
    <nct_id>NCT03125824</nct_id>
  </id_info>
  <brief_title>Soliton Planar Acoustic Wave Device System for Dermal Tattoo Clearing Human Trial Protocol</brief_title>
  <official_title>Soliton Planar Acoustic Wave Device System for Dermal Tattoo Clearing Human Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soliton</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedSource</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Soliton</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To further evaluate accelerated fading resulting from additional treatment sessions of
      Soliton AWD as accessory to laser in tattoo reduction treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To further evaluate accelerated fading resulting from additional treatment sessions of
      multi-pass Q-Switched laser with the Soliton Planar Acoustic Wave Device System (AWD) as an
      accessory to Q-Switched laser in tattoo reduction treatment.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 13, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate changes in accelerated fading of previously treated tattoos from original treatment with additional treatment sessions of Soliton Acoustic Wave Device as an accessory to laser treatment through comparison of photographic evidence. Changes are measured by comparing photos of the tattoos after the original treatment to photos of the tattoos after additional treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events for Safety Reporting</measure>
    <time_frame>12 weeks</time_frame>
    <description>Adverse Events and complications evaluated for severity and device relationship</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Tattooing</condition>
  <arm_group>
    <arm_group_label>Tattoos previously treated in Soliton 2016-001 trial</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Identical tattoos treated by Laser + AWD in Soliton's previous trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Soliton Acoustic Wave Device</intervention_name>
    <description>Treatment of tattoos with Soliton Acoustic Wave Device as an accessory to laser</description>
    <arm_group_label>Tattoos previously treated in Soliton 2016-001 trial</arm_group_label>
    <other_name>AWD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Range of Fitzpatrick skin color scores I to III

          -  The identical tattoo located on the arms, legs, and torso treated by Q-Switched laser
             and Laser + AWD during Soliton's previous 2016-001 clinical trial

          -  Black ink only. Other ink colors may be present, but areas of black only tattoo should
             meet inclusion criteria

          -  Approximately 1&quot; x 3&quot; tattoo with at least 30-50% of the treatment area containing
             black tattoo ink

        Exclusion Criteria:

          -  Subject is pregnant or planning to become pregnant during the duration of the study

          -  Medical disorder that would hinder the wound healing or immune response (no blood
             disorder, diabetes, inflammatory disease, etc.)

          -  Skin disorders (skin infections or rashes, scarring, moles,birthmarks, psoriasis,
             etc.)

          -  Any surgical procedure in the prior 3 months, or planned during the duration of the
             study

          -  Active electronic implants such as pacemakers, defibrillators, cochlear implants,
             nerve/brain stimulators, etc.

          -  Moderate to heavy tanning on and around the tattoo to be treated as determined by the
             Principle Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Cappelli, MD</last_name>
    <role>Study Director</role>
    <affiliation>Soliton</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SkinCare Physicians</name>
      <address>
        <city>Chestnut Hill</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2017</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

